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PPeripheral Arterial Disease
Progression of Peripheral Arterial Disease Predicts
Cardiovascular Disease Morbidity and Mortality
Michael H. Criqui, MD, MPH,*† John K. Ninomiya, PHD, MSc,* Deborah L. Wingard, PHD,*
Ming Ji, PHD,‡ Arnost Fronek, MD, PHD§
San Diego, California
Objectives The purpose of this study was to examine the association of progressive versus stable peripheral arterial disease
(PAD) with the risk of future cardiovascular disease (CVD) events.
Background An independent association between PAD, defined by low values of the ankle-brachial index (ABI), and future
CVD risk has been demonstrated. However, the prognostic significance of declining versus stable ABI has not
been studied.
Methods We recruited 508 subjects (59 women, 449 men) from 2 hospital vascular laboratories in San Diego, California.
ABI and CVD risk factors were measured at Visit 2 (1990 to 1994). ABI values from each subject’s earliest vas-
cular laboratory examination (Visit 1) were abstracted from medical records. Mortality and morbidity were
tracked for 6 years after Visit 2 using vital statistics and hospitalization data.
Results In multivariate models adjusted for CVD risk factors, very low (0.70) and, in some cases, low (0.70  ABI
0.90) Visit 2 ABIs were associated with significantly elevated all-cause mortality, CVD mortality, and combined
CVD morbidity/mortality at 3 and 6 years. Decreases in ABI of more than 0.15 between Visit 1 and Visit 2 were
significantly associated with an increased risk of all-cause mortality (risk ratio [RR]: 2.4) and CVD mortality (RR:
2.8) at 3 years, and CVD morbidity/mortality (RR: 1.9) at 6 years, independent of Visit 2 ABI and other risk factors.
Conclusions Progressive PAD (ABI decline 0.15) was significantly and independently associated with increased CVD risk.
Patients with decreasing ABI may be candidates for more intensive cardiovascular risk factor
management. (J Am Coll Cardiol 2008;52:1736–42) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.060m
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She association of peripheral arterial disease (PAD) with
uture cardiovascular disease (CVD) events and CVD and
otal mortality has been demonstrated in multiple studies.
ore recent studies using the ankle-brachial index (ABI),
he ratio of the ankle to the arm blood pressure, and other
oninvasive tests have shown the mortality association to be
ased largely on increased CVD, and independent of
raditional CVD risk factors (1–15).
Most studies have used a dichotomous definition of PAD
ased on an ABI cut point of 0.90. Although some studies
tratified ABI into additional categories for survival curve
nalysis, only a few have used additional ABI categories in
ull multivariate analysis. Many studies excluded patients
ith unusually high ABIs (e.g., 1.40), because such ABIs
rom the Departments of *Family and Preventive Medicine, †Medicine, and
Surgery and Bioengineering, University of California, San Diego, California; and the
San Diego State University, School of Public Health, San Diego, California. This
esearch was supported by National Institutes of Health Grant HL42973, NIH-
CRR General Clinical Research Center Program Grant M01 RR00827, and
merican Heart Association Grant-in-Aid No. 0050002N. William Hiatt, MD,
erved as Guest Editor for this article.p
Manuscript received February 5, 2008; revised manuscript received July 2, 2008,
ccepted July 7, 2008.ay reflect medial arterial calcification (MAC), which
recludes accurate ABI assessment.
See page 1743
Previous studies of the association of PAD with other
VD outcomes used ABI at baseline, and did not address
he potential additional significance of changes in ABI over
ime. The progression of PAD itself has received relatively
ittle attention (16–19). The prognostic significance of
AD progression for incident CVD events is unknown.
In the present study, the association between PAD, as
easured by the ABI, with CVD morbidity and mortality
as assessed in a group of vascular laboratory patients. The
ssociation of Visit 2 ABI with incident CVD morbidity
nd mortality was first examined, and the additional prog-
ostic significance of changes in ABI between Visits 1 and
was then explored.
ethods
ubjects were recruited for Visit 2 in 1990 to 1994 from
atients who had been seen in the previous 10 years for
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November 18, 2008:1736–42 Ankle-Brachial Indexoninvasive lower extremity arterial testing at the vascular
aboratories of the San Diego Veterans Administration Med-
cal Center (SDVAMC) or the University of California San
iego Medical Center (UCSDMC). Each patient’s first
ascular laboratory examination constituted Visit 1 for that
atient. Of 2,265 patients having such visits, 481 were
eceased and another 1,272 could not be located or declined
o participate. Informed consent was obtained from the
emaining 512 patients, who were examined for this study
Visit 2). A previous analysis of this cohort found that
articipants had slightly less advanced PAD than did
urviving nonparticipants and included a higher percent-
ge of women (13% vs. 8%), but were similar with respect
o age (17).
At Visits 1 and 2, systolic brachial pressure was measured
n both arms sphygmomanometrically with detection at the
hird finger by photoplethysmography, and ankle systolic
lood pressure was similarly measured with detection at the
oe (20,21). At Visit 2, subjects completed a health history
uestionnaire and the San Diego Claudication Question-
aire (SDCQ) (22). Basic laboratory, anthropometric, and
hysiologic measurements were obtained. Information from
he earliest prior vascular laboratory visit (Visit 1) was
bstracted for all subjects. The ABI at Visit 1 was used to
alculate the change in ABI in the period before Visit 2
mean  SD: 5.0  2.4 years). Four subjects failed to
rovide a Social Security number, the primary identifier
sed for morbidity and mortality follow-up (see the follow-
ng text); these subjects were excluded from subsequent
nalysis. This resulted in a final group of 508 subjects.
Mortality in the study cohort after Visit 2 was identified
sing Social Security Administration data available through
he end of 2002. A certified nosologist coded the causes of
eath based on death certificates. CVD morbidity, defined
s inpatient hospitalization, was identified from 2 sources.
lectronic hospital admission records for study participants
ere obtained from the SDVAMC. In addition, hospital-
zations were identified from data collected by the Califor-
ia Office of Statewide Health Planning and Development,
hich include all admissions to all nonfederal hospitals in
he state. Hospital discharge codes have been shown to
gree well with independent assessment for cardiovascular
iagnoses in Medicare patients (23). To protect patient
rivacy, data processing that involved the Office of State-
ide Health Planning and Development data was carried
ut on remote secure servers by Health Information Solu-
ions of Rocklin, California under contract with the Office
f Statewide Health Planning and Development.
Three end points were analyzed: all cause mortality, CVD
ortality, and combined CVD morbidity and mortality.
ortality was classified based on listed causes of death on
he death certificate. Morbidity was classified based on the
rincipal hospitalization diagnosis. A morbidity/mortality
nd point was identified as the earliest CVD morbidity or
ortality event for a subject. CVD mortality and morbidity
ere identified by International Classification of Disease-9 hmortality) or International Clas-
ification of Disease-9-Clinical
odification (morbidity) codes
n the range 401 to 437.9, ex-
luding 412.
The ABI for each leg was
omputed as the ratio of the
nkle pressure for that leg to the
igher of the left and right bra-
hial pressures. The higher bra-
hial pressure was used because
f the strong correlation between
AD and subclavian stenosis
24). The lower ABI value of the 2
egs was used. The ABI was cate-
orized into five ranges: 0.70,
.70 ABI0.90, 0.90 ABI1.00, 1.00  ABI 1.40,
nd 1.40. In addition, the set of models evaluating PAD
rogression and outcome had the change in ABI from Visit
, categorized into 3 ranges: 0.15, 0.15 to 0.15, and
0.15. This 0.15 cut point has been used to represent
linically significant ABI change in several studies (16–18).
n these latter models, subjects with Visit 1 or 2 ABI values
1.4 were excluded, since ABI change could be biased by
AC. The Visit 1 ABI value was also the lower of the 2
egs.
The following baseline cardiovascular risk factors were
ncluded in the analysis: age, gender, race (non-Hispanic
hite vs. other), high-density lipoprotein cholesterol, low-
ensity lipoprotein cholesterol, (log) triglycerides, self-
eported history of coronary heart disease (myocardial in-
arction, coronary artery bypass graft, or percutaneous
ransluminal coronary angioplasty), and self-reported his-
ory of stroke. Diabetes was included as a dichotomous
ariable based on plasma glucose 126 mg/dl among
ubjects reporting having fasted for 8 or more hours before
heir examination, or self-reported use of insulin or oral
ypoglycemics (25). Hypertension was included as a dichot-
mous variable based on systolic blood pressure 140 mm
g, diastolic blood pressure 90 mm Hg, or self-reported
se of hypertension medication (26). Smoking was included
n models as 2 separate variables: pack-years and smoking
tatus (current/former/never). The SDCQ was included as a
-level categorical variable, based on the most symptomatic
eg (22). Models involving the change in ABI were also
djusted for the time elapsed between ABI measurements.
t Visit 2, 32.9% of subjects reported earlier revasculariza-
ion for PAD, which was coded as a dichotomous variable.
Subjects were tabulated by morbidity and mortality sta-
us, and age-adjusted mean values of risk factors were
alculated within these groups. To test for proportional
azards over follow-up time, initially Cox models for the 3
nd points (all-cause mortality, CVD mortality, and com-
ined morbidity and mortality from CVD) were fit for 3-
nd 6-year durations from the time of Visit 2. The relative
Abbreviations
and Acronyms
ABI  ankle-brachial index
CHD  coronary heart
disease
CVD  cardiovascular
disease
MAC  medial arterial
calcification
PAD  peripheral arterial
disease
RR  risk ratio
SDCQ  San Diego
Claudication Questionnaireazard for all-cause and CVD mortality decreased over
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Ankle-Brachial Index November 18, 2008:1736–42ime, so separate logistic models at 3 and 6 years of
ollow-up were used for mortality analyses. For combined
VD morbidity and mortality, hazards remained propor-
ional during follow-up so Cox models were fit for full
6-year) follow-up only. The odds ratios from the logistic
odels and hazard ratios from the Cox models are both
ubsequently referred to as “risk” ratios. Visit 2 ABI was
onsidered in a first set of models; Visit 2 ABI and change
n ABI from Visit 1 were both included in a second set of
odels. Simultaneous inclusion in models of the Visit 2
BI category and the change category controls for regres-
ion to the mean and provides an estimate of the risk
ssociated with ABI change independent of the Visit 2 ABI.
ll models were adjusted for the CVD risk factors previ-
usly described above. Separate gender-specific models were
un for men only (numbers were too small for separate
odels for women). Models excluding subjects with previ-
us revascularization for PAD were also fit and were
ompared with the models using statistical adjustment for
evascularization for PAD. Separate models were also run
or subjects with or without a history of coronary heart
isease or stroke.
Smaller numbers necessitated simplified variables in these
tratified models: the SDCQ was reduced to a single
ichotomous variable (exertional leg pain, yes/no), and ABI
as reduced to a 3-level variable (0.70, 0.70  ABI
0.90, and 0.90  ABI 1.40) with values 1.40 ex-
luded. These simplified models were also used to test for
emographic and Peripheral Arterial Disease Characteristics by 3-Yortality Status, 508 Vascula Laboratory Patients, San Diego, Ca
Table 1 Demographic and Peripheral Arterial Disease CharacteMortality Status, 508 Vascular Laboratory Patients, Sa
Variable*
Alive, No CVD
Hospitalization
CVD
n 302
Age (yrs) 67.2
Gender (% female) 14.6
Race (% other than non-Hispanic white) 13.2
San Diego Claudication Questionnaire
(% of subjects)†
No pain 27.9
Pain at rest 24.4
Non-calf pain 2.7
Non-rose calf pain 13.8
Rose 29.6
Visit 2 ABI (%)
1.40‡ 1.3
1.00  ABI 1.40 39.4
0.90  ABI 1.00 9.3
0.70  ABI 0.90 17.7
0.70 32.2
ABI change, Visit 1 to Visit 2 (%)
0.15 25.9
Between 0.15 and 0.15 63.1
0.15 11.0
Variables other than age, gender, and race are adjusted for age, gender, and race, except as note
ge/gender/race adjustment by logistic regression; percentages are raw, not significantly different
p  0.0001.
ABI  ankle-brachial index; CVD  cardiovascular disease; SDCQ  San Diego Claudication Questionntatistical interaction of history of coronary heart disease and
troke with ABI and ABI change in the whole cohort.
nteractions of ABI and ABI change with history of
evascularization for PAD were also modeled. All analyses
ere performed using SAS software (SAS Institute, Inc.,
ary, North Carolina).
The study protocol was approved by the institutional
eview boards of SDVAMC and the University of Califor-
ia San Diego, and the California State Committee for the
rotection of Human Subjects.
esults
hree years after Visit 2, 302 of 508 subjects (59.4%) were
live and had not been hospitalized for CVD (reference
roup). There were 121 (23.8%) who had been hospitalized
or a principal diagnosis of CVD but had not died of CVD.
ixty-five (12.8%) were dead due to CVD, and the remain-
ng 20 (3.9%) were dead from another cause without
revious CVD hospitalization.
Table 1 shows that subjects with CVD hospitalization
nd deceased subjects were somewhat older at baseline than
ubjects in the reference group. The groups did not differ
ignificantly with respect to claudication symptoms. At
aseline, the age-, gender- and ethnic-adjusted percentage
f reference group subjects who had very low ABI (0.70)
as 32.2%; the corresponding proportion was significantly
igher among subjects hospitalized for nonfatal CVD
orbidity/ia, Recruited 1990 to 1994
s by 3-Year Morbidity/
go, California, Recruited 1990 to 1994
alization But
D Death Dead From CVD
No CVD Hospitalization,
Dead From Non-CVD Cause
1 65 20
9.1§ 70.2§ 69.1
7.4§ 6.2 10.0
0.7 10.8 15.0
0.7 21.2 20.2
9.6 34.8 30.1
2.2 6.4 4.0
7.8 17.3 14.7
8.4 18.6 29.2
1.7 3.1 0.0
9.2 10.7¶ 26.6
8.4 6.4 14.9
6.4 16.6 24.7
4.3§ 63.2¶ 33.8
1.9 15.1 19.9
8.0 55.0 61.1
0.2§ 29.9 19.0
CQ categories are listed from best to worst, as used to determine worst leg. ‡Data too sparse for
er’s exact test. Significantly different from “Alive, no CVD hospitalization:” §p 0.05; p 0.001;ear Mlifo n
ristic
n Die
Hospit
No CV
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November 18, 2008:1736–42 Ankle-Brachial Index44.3%; p  0.05) as well as among subjects who died of
VD (63.2%; p  0.0001). The adjusted proportion of
atients with “normal” ABI (1.00ABI1.40) was higher
n the reference group (39.4%) than it was among subjects
ospitalized for nonfatal CVD (29.2%, p  0.05) and
mong subjects dying of CVD (10.7%, p  0.0001). The
roportions of subjects in the other Visit 2 ABI categories
id not differ significantly across groups.
Compared with the reference group, a significantly
igher adjusted proportion of subjects hospitalized with
onfatal CVD had decreases in ABI of more than 0.15
etween Visits 1 and 2 (20.2% vs. 11.0%, p  0.05). This
as even more pronounced for subjects who died of CVD
29.9%, p  0.001).
Table 2 compares the 4 morbidity/mortality groups on
ther risk variables. Compared with the reference group,
ubjects with CVD hospitalization and CVD decedents had
ignificantly more hypertension and diabetes, as well as Visit
coronary heart disease. CVD decedents also had a greater
troke prevalence at Visit 2 (27.4% vs. 14.2%, p  0.05).
Of 508 subjects, 482 (94.9%) had complete information on
ll adjustment variables and Visit 2 ABI and were included in
he multivariate models presented in Figure 1. The 26 subjects
ith missing data did not differ significantly from the other
ubjects with respect to age, gender, race, or Visit 2 ABI.
Figure 1 shows risk ratios (RRs) for Visit 2 ABI as a 5-level
ategorical variable, for 3 end points: all-cause mortality, CVD
ortality, and CVD morbidity/mortality. All models were
ully adjusted for CVD risk factors as well as claudication and
eripheral revascularization history. Results for 3- and 6-year
ollow-ups are shown for mortality. Compared with subjects in
he reference category (1.00 ABI1.40), subjects with very
ow ABI (0.70) had a significantly elevated risk of events for
ll end points at both 3- and 6-year follow-ups. Risk ratios
anged from 1.8 (p 0.03) for 6-year all-cause mortality to 9.2
p  0.0001) for 3-year CVD mortality.
Subjects with low ABI (0.70  ABI  0.90) had
ignificantly elevated risks of 3-year all-cause mortality (RR:
VD Risk Factors by 3-Year Morbidity/Mortality Status,08 Va cul r Laboratory Patients, San Diego, California, Recruited
Table 2 CVD Risk Factors by 3-Year Morbidity/Mortality Statu508 Vascular Laboratory Patients, San Diego, Californi
Variable at Visit 2*
Alive, No CVD
Hospitalization
CVD Ho
No
n 302
BMI (kg/m2) 26.9
HDL cholesterol (mg/dl) 46.9
LDL cholesterol (mg/dl) 131.5
Log triglycerides (mg/dl) 4.9
Diabetes (%) 26.5
Hypertension (%) 74.5
Pack-years, n 48.1
Current smokers (%) 28.6
Past smokers (%) 57.0
Coronary heart disease history (%) 31.8
Stroke history (%) 14.2Variables are adjusted for age, gender, and race. Significantly different from “Alive, no CVD hospitalizat
BMI  body mass index; CVD  cardiovascular disease; HDL  high-density lipoprotein; LDL  low-de.3, p  0.01), 3-year CVD mortality (RR: 4.3, p  0.01),
nd 6-year CVD morbidity/mortality (RR: 1.6, p  0.05).
ubjects with ABI in the 0.90  ABI 1.00 range had risk
atio estimates 1 for all end points and durations, but
hese results did not achieve statistical significance.
There were only 8 subjects in the high ABI category
1.40). Nonetheless, for 3-year CVD mortality, a statistically
ignificant risk ratio of 8.6 (p  0.03) was observed. Signifi-
antly elevated risk in the high ABI category was also observed
or 6-year CVD morbidity/mortality (RR: 2.5, p 0.05). Risk
atio point estimates for all other end points and durations
ere 1, but did not achieve statistical significance.
Table 3 shows risk ratios and p values for the change in
BI between Visits 1 and 2. Adjusted for Visit 2 ABI and
ther potential confounders, compared with an ABI change
f 0.15, a decrease in ABI of 0.15 was significantly
ssociated with 3-year all-cause mortality (RR: 2.4, p 
.01) and 3-year CVD mortality (RR: 2.8, p  0.01).
stimated risk ratios at 6 years were1, but did not achieve
tatistical significance for any of the outcomes.
The ABI change models in Table 3 were adjusted for
isit 2 ABI using the categorical ABI variable. In the ABI
hange models, very low Visit 2 ABI (0.70) was signifi-
antly associated with higher risk of all 3 outcomes at all
urations except all-cause mortality at 6 years. Compared
ith the models in Figure 1, the RR estimates for low and
ery low Visit 2 ABI were generally lower in Table 3,
uggesting that associations for Visit 2 ABI in Figure 1 were
artially due to an ABI decline from Visit 1.
In multivariate models that excluded subjects who had
ndergone procedures for peripheral arterial disease before
isit 2 (not shown), the observed associations were similar in
irection and magnitude to the models presented previously.
his was also true of models in men only (not shown).
Separate models were also run based on history of coronary
eart disease (CHD) or stroke. These stratified models also
howed independent and significant contributions of Visit 2
BI and change in ABI to CVD morbidity and mortality.
0 to 1994
cruited 1990 to 1994
zation But
eath Dead From CVD
No CVD Hospitalization,
Dead From Non-CVD Cause
65 20
26.3 26.7
43.9 45.7
133.3 112.1†
4.9 4.8
‡ 50.4‡ 40.2
‡ 88.8† 74.5
52.3 54.2
30.2 30.2
47.1 65.0
‡ 48.8† 9.5†
27.4† 29.5199
s,
a, Re
spitali
CVD D
121
27.8
45.0
131.5
5.0
45.1
90.8
47.5
29.0
55.1
52.4
20.5ion:” †p  0.05; ‡p  0.001.
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Ankle-Brachial Index November 18, 2008:1736–42In models including statistical interaction between se-
ected variables, ABI and ABI change demonstrated no
ignificant interactions with history of CHD and stroke,
orrected for the large number of potential interactions
ested. The same was true of interactions of ABI with ABI
hange, and of ABI and ABI change with history of
evascularization for PAD.
iscussion
he observed association of low ABI values with future risk
f cardiovascular disease morbidity and mortality in the
resent study is generally consistent with that reported in
ther studies (1–15), as is the predictive value of a high
1.40) ABI (14,15,27).
In the present study, without including ABI change vari-
bles, RR point estimates increased monotonically with lower
BI, with the 0.70 category RR reaching statistical signifi-
ance in all but 1 model. A number of studies have presented
vidence for a dose–response relationship between lower ABI
nd future CVD events. In some cases this evidence was
imited to Kaplan-Meier curves without full multivariate ad-
ustment (6,8,9). Using a Cox model with multivariate adjust-
ent, Tsai et al. (12) reported a borderline significant trend for
BI categories for the end point of ischemic stroke. Other
tudies using Cox models with multivariate adjustment have
Outcome by ABI Ca
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Figure 1 3- and 6-Year All-Cause Mortality and CVD Events by
Vascular Laboratory Patients, San Diego, California, R
Mortality model are logistic, morbidity/mortality model is Cox. Models adjusted for
density lipoprotein cholesterol, log triglycerides, diabetes, hypertension, pack-years
tory of stroke, claudication status and history of surgery for peripheral artery disea
diovascular disease.ound such a trend toward higher CVD risk in successively aower ranges of ABI, but did not find all the successive
ategories to be significantly different or, in some cases, even
onotonically increasing (13–15).
Decreases in ABI of more than 0.15 were associated with a
ignificantly higher risk of events, independent of both Visit 2
BI and time elapsed between Visits 1 and 2. In the present
tudy, 16.7% of subjects had such decreases, suggesting that
his is reasonably common in a vascular laboratory population.
ince only two-thirds of subjects met a standard PAD defini-
ion at Visit 2, these results refer to overall progression of
eripheral atherosclerosis in a vascular laboratory cohort, rather
han progression of clinical PAD per se. It has been previously
bserved that progression of coronary atherosclerosis is predic-
ive of subsequent coronary events (28,29). To our knowledge,
he present study is the first to demonstrate the independent
ignificance of PAD progression for incident CVD events.
Cronenwett et al. (16) compared patients whose PAD either
emained stable or progressed, based on reduced walking
olerance. They found that the change in mean ABI over the
bservation period was significantly different in the 2 groups,
ith a larger decrease among the patients whose symptoms
rogressed, but that the mean ABI at the start of the period did
ot differ between the 2 groups. The same was true comparing
atients undergoing surgery for PAD with those not having
perations. Cronenwett concluded that initial ABI is “an unsuit-
ry at 3 Years
lity
Reference
*
ry at 6 Years
ty CVD Morbidity/Mortality
Reference
***
*
*
ategory,
ited 1990 to 1994
ender, race, body mass index, high-density lipoprotein cholesterol, low-
ing, smoking status (current/past/never), history of coronary heart disease, his-
 0.05; **p  0.01; ***p  0.001. ABI  ankle-brachial index; CVD  car-tego
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November 18, 2008:1736–42 Ankle-Brachial Indexdeteriorating ABI” is necessary to plan timely operative inter-
ention. This parallels the association of change in ABI with
VD risk demonstrated in the present study, although in this
tudy low ABI remained predictive in many models.
The ability of ABI to predict CVD outcomes even in a
igh-morbidity, high-mortality vascular laboratory population
s itself a new finding; previously, this has been demonstrated
n such a population only with respect to all-cause mortality
30). This is of practical clinical interest, since at present most
BI measurements are taken in such settings.
In separate models, subjects with and without history of
HD or stroke showed associations similar to the whole
roup. Newman et al. (11) also reported associations be-
ween low ABI and CVD in separate analyses of subjects
ith and without a baseline history of disease. Although
any earlier studies excluded subjects with baseline CVD,
n association between PAD and adverse outcomes has been
emonstrated in several cohorts consisting exclusively of
ubjects with CVD, such as myocardial infarction (31,32)
nd angina patients (33).
In most previous studies, high ABI values (e.g., 1.40)
ere excluded from analysis, because they were thought to
e due to MAC, which makes arteries difficult to compress
nd yields erroneously high ankle blood pressures. MAC is
ost common in patients with diabetes and renal disease,
nd has been shown to be independently associated with
ardiovascular disease morbidity and mortality in these
ssociation of 3- and 6-Year CVD Outcomes With Visit 2 ABI and Crom Vis t 1 in ABI, Vascular Labora ory Patien s, San Diego, Calif
Table 3 Association of 3- and 6-Year CVD Outcomes With VisitFrom Visit 1 in ABI, Vascular Laboratory Patients, San
ABI
All-Cause Mortality
RR (95% CI) p Value
3 yrs
Visit 2 ABI
1.00  ABI 1.40 1.0
0.90  ABI 1.00 2.2 (0.7–6.7) 0.17
0.70  ABI 0.90 2.5 (1.0–6.3) 0.05
0.70 3.9 (1.7–8.9) 0.001
ABI change
Increase 0.15 0.8 (0.3–1.7) 0.53
Change 0.15 1.0
Decrease 0.15 2.4 (1.2–4.8) 0.01
6 yrs
Visit 2 ABI
1.00  ABI 1.40 1.0
90  ABI 1.00 1.5 (0.7–3.5) 0.31
0.70  ABI 0.90 1.1 (0.5–2.2) 0.81
0.70 1.6 (0.9–3.0) 0.12
ABI change
Increase 0.15 0.8 (0.5–1.5) 0.53
Change 0.15 1.0
Decrease 0.15 1.2 (0.6–2.2) 0.61
Mortality models are logistic; morbidity/mortality models are Cox. Models include Visit 2 ABI and
ow-density lipoprotein cholesterol, log triglycerides, diabetes, hypertension, pack-years smoking, sm
nd peripheral revascularization.
CI  confidence interval; RR  risk ratio; other abbreviations as in Table 1.roups (34,35). These findings are consistent with our Aesults, and with results from population studies (14,15,27).
hus, a high ABI predicts high CVD risk, perhaps because
majority of such patients have underlying PAD (36,37).
The present study has a number of potential limitations.
actors that predispose patients to participate in a clinical
tudy may skew recruitment in unknown ways, although the
vailable information on nonparticipants did not suggest
trong selection effects (17). Morbidity follow-up did not
nclude hospitalization outside California or at Veterans
dministration facilities other than SDVAMC, although
hese numbers are likely to be small. The time elapsed
etween the Visit 1 and 2 ABI measurements should ideally
ave been uniform. Since this was not feasible, models
ncluded adjustment for differences in the time elapsed
etween ABI measurements.
onclusions
hese data provide the first evaluation of the relation of PAD
rogression to subsequent CVD morbidity and mortality, and
how a consistent and significant association, independent of
he severity of PAD and traditional CVD risk factors. The
resent study also confirms the independent association of very
ow and low ABI (0.70 and 0.70  ABI 0.90) with an
ncreased risk of all-cause mortality, CVD mortality, and
ombined CVD morbidity/mortality, with a greater increase in
isk in the lowest ABI group, as well as the association of high
e, Recruited 1990 to 1994*
I and Change
o, California, Recruited 1990 to 1994*
CVD Mortality CVD Morbidity/Mortality
(95% CI) p Value RR (95% CI) p Value
1.0
(0.5–10.0) 0.30
(0.9–9.4) 0.08
(2.4–18.6) 0.001
(0.3–2.1) 0.65
1.0
(1.3–6.0) 0.01
1.0 1.0
(0.7–4.7) 0.24 1.1 (0.6–1.9) 0.70
(0.6–3.0) 0.40 1.5 (1.0–2.3) 0.04
(1.2–4.7) 0.02 1.9 (1.3–2.7) 0.001
(0.6–2.2) 0.66 1.0 (0.7–1.4) 0.99
1.0 1.0
(0.6–2.4) 0.56 1.3 (0.9–1.8) 0.21
nge and are adjusted for age, gender, race, body mass index, high-density lipoprotein cholesterol,
status (current/past/never), history of coronary heart disease, history of stroke, claudication statushangornia
2 AB
Dieg
RR
2.2
2.9
6.6
0.8
2.8
1.8
1.4
2.4
1.2
1.2
ABI cha
okingBI values (1.40) with an increased CVD event risk. In
a
a
d
A
T
a
R
U
C
m
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
K
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Ankle-Brachial Index November 18, 2008:1736–42ddition to the known prognostic significance of a low ABI,
nd more recently, a high ABI, the evidence here shows a
eteriorating ABI also independently carries a poor prognosis.
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